Preclinical

ARCA Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201

Lead Product(s): rNAPc2

Therapeutic Area: Hematology Product Name: AB201

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 12, 2020

Details:

The FDA provided feedback for ARCA's clinical development plans for evaluating AB201 as a potential treatment for patients with severe COVID-19.

ARCA Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

ARCA Biopharma Announces $9.4 Million Registered Direct Offering

Lead Product(s): rNAPc2

Therapeutic Area: Hematology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: JonesTrading Institutional Services

Deal Size: $9.4 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 01, 2020

Details:

ARCA anticipates that the net proceeds from this offering will be used to initiate its clinical trial of AB201 and for working capital and general corporate purposes.

ARCA Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy

Lead Product(s): rNAPc2

Therapeutic Area: Hematology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

ARCA Biopharma

ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201

ARCA Biopharma

ARCA Biopharma Announces $9.4 Million Registered Direct Offering

ARCA Biopharma

ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy